Custom Search

"WHAT IS POD? OUR NEW SERVICE

Posted by PANKS On FEB- 2011

POD

Evidence Based Dentistry

Posted by PANKS On OCT- 2010

Evidence Based Dentistry

Dean Charles Bertolami Receives Distinguished Award

Posted by PANKS On OCT- 2010

Award Winning Dr. Charles Bertolami, Dean of NYU

GUIDE TO STUDY IN US

Posted by PANKS On Month - Day - Year

This is a series of articles for coming down to US- A Step-by Step Guide. The Articles will be numerous and reliable simply because I have been through the same process already and have gained some credible information on how to do things. Above all it is FREE.MedAbroad is your free consultant.

NATHAN WOLF: AIDS RESEARCH

Posted by PANKS On Month - Day - Year

Global Viral Forecasting Initiative leader Nathan Wolfe called as Indiana Jones of Virus Hunting. He talked about AIDS when I happened to meet him for a while on AAAS conference in Boston 2008. Dr. Wolfe is being involved in extensive AIDS Research. He says that "Pandemics are Avoidable"

NEWS

Posted by PANKS On Month - Day - Year

A dedicated corner for NEWS happening in Medical, Dental, Public Health and Allied Health Sciences which will be posted here as it happens. Feel the Power of Information from around the World!!

MEDABROAD TV

Posted by PANKS On Month - Day - Year

This our dedicated VIDEOS SECTION for NBDE etc , please click MEDABROAD TV on top to visit VIDEOS. Also feel free to drop in your ideas and suggestions at: feedback@medabroad.info

OUR PHILOSOPHY

Posted by PANKS On Month - Day - Year

Our philosophy rolls around Help N Be Helped. We believe in Helping people with information or anything thats possible and hope that you also follow the same, making great friends for life. All ideas are taken as a stepping stone for making the philosophy Help N Be Helped a greater success.

Showing posts with label HIV. Show all posts
Showing posts with label HIV. Show all posts

Elite HIV controllers

by MedAbroad
 This is an awesome interview of someone who is literally UNTOUCHED by HIV virus, Bob Hoff.
These people are HIV positive for decades and are called as HIV Elite group. Their CD4 counts (a type of cell that signifies if a person is HIV positive and has reached the level of AIDS) DO NOT fall as it falls in other HIV positive patients in all these years.

Could they be OUR future saviors in preventing and hence curing HIV/AIDS?







Research UpdateA new CDC study called the TDF2 study, along with a separate trial released on July 14, 2011, provide the first evidence that a daily oral dose of antiretroviral drugs used to treat HIV infection can reduce HIV acquisition among uninfected individuals exposed to the virus through heterosexual sex. See Details here

P.S: The study below which was the initial study talks about MSM (Gay men having sex with Gay Men)

The recent research in HIV has shown that a combination of two antiretrovirals (ARVs)  called as Truvada could significantly reduce the likelihood of HIV infection among gay men and other men who have sex with men (MSM).  Gay men and MSM seems to be the major population with highest risk of HIV infection. The result showed that overall the efficacy is 43.8% among study participants. 

Salient points from the Research
  • Two anti-retrovirals included a combination of tenofovir and emtricitabine called as Truvada
  • Efficacy of the combination drug depended upon who took the drugs consistently.
  • But prevention is better than cure, even with this combination drug i.e: It does not negate the positive effects of regular prevention like counseling and condoms. As  amfAR CEO Kevin Robert Frost suggested These results suggest that PrEP could be a very important prevention tool for gay men and MSM when used in combination with other prevention interventions including condoms.”
  •  The results of the initial landmark study requires some more studies to topics like adherence, safety, and the potential to impact HIV incidence,” Collins, amfAR’s vice president and director of public policy said.
  • This trial was for gay men and MSMs, so a new or similar study is required for other potential High-Risk patients like  injection drug users (IDUs), female sex workers, or heterosexual women and men.  
  • Ofcourse, there are potential risks in taking PrEP, including side effects and possible drug resistance. Further safety analysis will be conducted over the coming year.
So what was Pre-exposure Prohylaxis Intitative or iPrEx Study?

The Pre-Exposure Prophylaxis (PrEP) Initiative, or iPrEx study, was a clinical trial aimed at determining whether two ARVs currently used to treat HIV/AIDS could also help prevent HIV infection among MSM at elevated risk of HIV infection. Two thousand four hundred and ninety-nine participants in six countries were instructed to take either one tablet of Truvada (a combination of tenofovir and emtricitabine) or a placebo, once a day. The trial began in 2007. Read in detail about the study at The New England Journal Of Medicine


amfAR Vice President and Director of Public Policy Chris Collins was interviewed about the iPrEx study results on PBS NewsHour on November 25, 2010, with NIAID Director Anthony Fauci.

Disclaimer: The information in the article is for reference purposes only. These are studies and we take full care to explain the importance of the relevant researches and NEVER intend to change the course of treatment you or any of your friends and/or relatives are undergoing. The idea is to present the latest research in the Medical and Dental World. Be influenced and Inspired accordingly. The author does not hold any responsibility for misinterpretation of the articles.

Today, WHO endorsed a new and novel rapid test for tuberculosis (TB), especially relevant in countries most affected by the disease. The test could revolutionize TB care and control by providing an accurate diagnosis for many patients in about 100 minutes, compared to current tests that can take up to three months to have results.

Some Key Facts:
  • It is an automated test, free from any human error.
  •  It is a very sensitive test, even at low volume of TB in HIV patients, this test will be able to diagnose TB.
  • Can be used as the Initial TB test
  • Uses Nucleic Acid Amplification Test which is fully automated and based on DNA testing
  • Diagnoses both TB and Rifampin Resistance (used in TB treatment and one of the drugs for which MDR or Multiple Drug Resistance is present)
  • Takes less than 2 hours to detect.
  • People can get immediate treatment.
  •  FIND, the company behind this TB test, has negotiated with many organizations to provide the tests for 75% discount.
  • This will result in a 3 fold rise in Drug resistance TB cases in the near future
  • As WHO puts it, the delay of the diagnosis as in previous diagnostic methods which can take even months, results in continuous spreading of the disease. The early diagnosis will be safer for all the professionals involved and of course for public, who will be early diagnosed and treated.
  • The test is planned to be systematically implemented in 2011
  • There are minimal dangers to perform such a test
  • The new technology will not replace the need for microscopy, conventional culture and/or existing
    molecular methods such as line probe assay.Conventional microscopy and culture are also still necessary to monitor treatment response once patients are taking anti-TB drug.
  • Advantage of early detection of TB and preventing spread of TB between people.
 MedA


Post your comments below, what do you think about this news!!

Source: WHO

Blog Widget by LinkWithin